Shearman & Sterling advised JW (Cayman) Therapeutics Co. Ltd., a China-based cancer cell therapy developer, in connection with its primary listing on the Main Board of The Stock Exchange of Hong Kong Limited and global offering with a size of approximately HK$2.325 billion ($300 million).

JW (Cayman) Therapeutics Co. Ltd is a global leading clinical stage cell therapy platform company founded by Juno Therapeutics and WuXi AppTec. Its vision is to develop innovative cell therapies for the China market to transform the treatment of cancer for Chinese patients. Since its establishment in 2016, the company has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors.

The Team